Education
About Us
Working with TipRanks
Follow Us
Alphatec (DE:L1Z1)
:L1Z1
L1Z1 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€4.36 - €11.90
Previous CloseN/A
Volume150.00
Average Volume (3M)18.00
Market Cap
€1.62B
Enterprise ValueN/A
Total Cash (Recent Filing)€153.24M
Total Debt (Recent Filing)$581.27M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Jul 31, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding146,172,700
10 Day Avg. Volume5
30 Day Avg. Volume18
Financial Highlights & Ratios
PEG Ratio12.11
Price to Book (P/B)31.84
Price to Sales (P/S)0.00
P/FCF Ratio-21.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€16.21Price Target Upside53.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Alphatec Holdings News
PremiumCompany Announcements
Alphatec’s Earnings Call Highlights Strong 2025 Start
PremiumCompany Announcements
Alphatec Reports Strong Q1 2025 Growth and Raises Guidance
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAlphatec reported total revenues of $169M for the quarter, slightly higher than consensus estimate of $168M.
Market PositionATEC's work to drive clinical differentiation with its enabling technologies and procedural solutions appears to be paying off, as ATEC notes it is an 8% market share player, the largest pure-play spine company.
Strategic ExecutionATEC's OUS strategy is progressing with regulatory clearances in Australia and Japan progressing as planned.
Bears Say
Insurance ReimbursementATEC has not seen any change or disruption to its SafeOp franchise despite changes in reimbursement by a large insurance provider affecting competitors.
Tariff ImpactATEC's tariff impact is manageable in the low-single digit millions.
Options Prices
Currently, No data available
---
Ownership Overview
19.29% Insiders
13.17%
Mutual Funds
20.17% Other Institutional Investors
37.47% Public Companies and Individual Investors
L1Z1 FAQ
What was Alphatec’s price range in the past 12 months?
Alphatec lowest stock price was €4.36 and its highest was €11.90 in the past 12 months.
What is Alphatec’s market cap?
Alphatec’s market cap is €1.62B.
When is Alphatec’s upcoming earnings report date?
Alphatec’s upcoming earnings report date is Jul 31, 2025 which is in 55 days.
How were Alphatec’s earnings last quarter?
Alphatec released its earnings results on May 01, 2025. The company reported -€0.1 earnings per share for the quarter, beating the consensus estimate of -€0.102 by €0.003.
Is Alphatec overvalued?
According to Wall Street analysts Alphatec’s price is currently Undervalued.
Does Alphatec pay dividends?
Alphatec does not currently pay dividends.
What is Alphatec’s EPS estimate?
Alphatec’s EPS estimate is -0.04.
How many shares outstanding does Alphatec have?
Alphatec has 146,172,700 shares outstanding.
What happened to Alphatec’s price movement after its last earnings report?
Alphatec reported an EPS of -€0.1 in its last earnings report, beating expectations of -€0.102. Following the earnings report the stock price went down -4.04%.
Which hedge fund is a major shareholder of Alphatec?
Currently, no hedge funds are holding shares in DE:L1Z1
Alphatec Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€16.21 (53.96% Upside)
€16.21 (53.96% Upside)
Blogger Sentiment
Bullish
DE:L1Z1 Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $145.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.15%
12-Months-Change
Fundamentals
Return on Equity
-291.71%
Trailing 12-Months
Asset Growth
1.41%
Trailing 12-Months
Company Description
Alphatec
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.
L1Z1 Company Deck
L1Z1 Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
ATEC reported a strong start to 2025 with significant revenue growth, increased surgeon adoption, and improved cash flow management. However, the company faced challenges with gross margin declines and tariff-related costs. The strategic expansion in international markets and advancements in their procedural solutions provide a positive outlook.Read More>L1Z1 Stock 12 Month Forecast
Average Price Target
€16.21
▲(53.96%Upside)